表紙
市場調查報告書

神經學市場:BCC Research 的概要

Neurology Market: A BCC Research Overview

出版商 BCC Research 商品編碼 891234
出版日期 內容資訊 英文 194 Pages
訂單完成後即時交付
價格
Back to Top
神經學市場:BCC Research 的概要 Neurology Market: A BCC Research Overview
出版日期: 2019年07月18日內容資訊: 英文 194 Pages
簡介

全球神經學市場預測將從2019年的333億美元,到2024年擴大到394億美元,在預測期間中預計為3.5%的年複合成長率 (CAGR) 。

本報告提供全球神經學市場相關調查,市場概要與產業分析,世界市場趨勢分析與成長率的預測,各疾病的定量分析,各種治療藥相關討論,競爭情形的檢討,及主要企業簡介等資訊。

第1章 簡介

第2章 摘要、亮點

第3章 市場、技術概要

  • 神經疾病:概要
  • 疾病的背景
    • 帕金森氏症
    • 阿茲海默症
    • 思覺失調症
    • 躁鬱症
    • 憂鬱症
    • 癲癇性疾病
    • 泛自閉症障礙 (ASD)
  • 神經保護藥
  • 醫藥品開發法規
    • 美國
    • 加拿大
    • 墨西哥
    • 歐洲
    • 亞太地區
    • 其他 (RoW)
  • 醫療費償付形勢

第4章 市場動態

  • 市場成長促進因素
  • 阻礙市場成長要素

第5章 全球神經學市場

  • 疾病的各徵兆

第6章 全球帕金森氏症市場

  • 市場概要
  • 市場:各醫藥品分類
  • 多巴胺作用
  • 多巴胺促效劑
  • 酵素抑制劑
  • 其他帕金森氏症藥
  • 抗帕金森氏症藥市場:各地區
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲
  • 全球企業佔有率分析

第7章 全球阿茲海默症市場

  • 市場概要
  • 市場:各作用機制
  • AChEI
  • NMDA藥
  • 全球阿茲海默症治療藥市場:各地區
  • 北美
  • 歐洲
  • 其他
  • 產業結構

第8章 全球精神性障礙市場

  • 市場概要
  • 市場:各醫藥品分類
  • D2拮抗劑
  • D2/5HT2A拮抗劑
  • D2 Partial拮抗劑
  • 全球精神性障礙治療藥市場:各地區
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲
  • 全球企業佔有率分析
  • 非專利抗精神病藥帶給市場的影響

第9章 全球癲癇性障礙市場

  • 市場概要
  • 市場:各醫藥品分類
  • 第1代抗癲癇藥
  • 第2代的抗癲癇藥
  • 第3代抗癲癇藥
  • 全球抗癲癇藥市場:各地區
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲
  • 競爭情形

第10章 全球泛自閉症障礙 (ASD) 市場

  • 市場概要
  • 市場:各醫藥品標示資訊
  • 已通過核准醫藥品
  • 未核准醫藥品
  • 全球ASD治療藥市場:各地區
  • 北美
  • 歐洲
  • 其他
  • 產業結構

第11章 全球腦瘤治療市場

  • 市場概要
  • 市場:各治療類型
  • 化療
  • 標靶治療
  • 免疫療法
  • 腦瘤治療市場:各地區
  • 北美
  • 歐洲
  • 亞太地區
  • 其他
  • 企業佔有率分析

第12章 開發平台分析

第13章 競爭情形

第14章 企業簡介

第15章 附錄:縮寫

第16章 參考資料

目錄
Product Code: PHM215A

Report Highlights:

The global market for neurology should grow from $33.3 billion in 2019 to $39.4 billion by 2024 at a compound annual growth rate (CAGR) of 3.5% for the period of 2019-2024.

Psychotic neurological disorder market should grow from $13.4 billion in 2019 to reach $14.7 billion by 2024 at a CAGR of 1.8% for the period of 2019-2024.

Brain tumor neurological disease market should grow from $1.3 billion in 2019 to reach $2.1 billion by 2024 at a CAGR of 6.1% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers therapeutics used in treatment of neurological disorders.

The report highlights the current and future market potential of neurology medicines and provides a detailed analysis of the competitive environment, regulations, epidemiology of neurological diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.

The report details market shares of neurology based on different disease indication. Based on neurological disorders the market is segmented into Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, Autism Disorders, and Brain Tumor Diseases. Each diseases segment covers therapeutics and regional analysis.

The market of Parkinson Diseases covers anti-Parkinson's drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into dopaminergic, enzyme inhibitors, dopamine agonists and other Anti-Parkinson's medications. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.

The market of Alzheimer Diseases covers anti-Alzheimer drugs. The market is segmented based on mechanism of action of drugs and region. Based on drug class the market is segmented into AChE inhibitors and NMDA antagonist. Based on region the market is segmented into North America, Europe, and Rest of the World.

The market of psychotic diseases covers antipsychotic drugs. The market is segmented into drug class and region. Based on drug, the market is segmented into D2 antagonists, D2/5HT2A antagonists, and D2 partial agonist. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.

The market of Epileptic Diseases covers Anti-Epileptic Drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into first generation drugs, second generation drugs, and third generation drugs. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.

The market of autism disorder covers autism disorder therapeutics. The market is segmented into drug based on labelled information and region. Based on drug class the market is segmented into ASD-labeled pharmaceuticals and Off-label pharmaceuticals. Based on region the market is segmented into North America, Europe, and Rest of the World.

The market of brain tumor covers brain tumor therapeutics. The market is segmented into therapy type and region. Based on therapy type, the market is segmented into chemotherapy and targeted therapy. Based on region, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World.

For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on drug manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

  • 15 data tables and 22 additional tables
  • An in-depth overview and industry analysis of the global market for neurology medicines
  • Analyses of the global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Historical background on neurological disorders and therapeutics, growing prevalence of neurological disorders, increasing research and development activities regarding neurology research, and analysis of the factors influencing the market
  • Quantitative analysis of the neurology therapeutics market covering Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, Autism Disorders, and Brain Tumor Diseases
  • Discussion of various therapeutics used for treatment of different neurological disorders, along with coverage of novel pipeline, patent expiry of blockbuster drug and new drug approvals
  • Reviews of the competitive landscape, key strategies adopted by market players, mergers and acquisitions details, pipeline analysis covering ongoing clinical trials and promising forthcoming neuroscience therapies in late stage etc.
  • Details company profile of leading participants within the neurology market including, AbbVie, Biogen, GlaxoSmithKline Plc, Johnson & Johnson, and Sun Pharmaceuticals Industries Ltd.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing this Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Neurological Disorders: Overview
  • Disease Background
    • Parkinson Disease
    • Alzheimer Disease
    • Schizophrenia
    • Bipolar Disorders
    • Depression
    • Epileptic Disorders
    • Autism Spectrum Disorders
  • Neuroprotective Agents
    • Neuroprotective Strategies
  • Drug Development Regulations
    • U.S.
    • Canada
    • Mexico
    • Europe
    • Asia-Pacific
    • ROW
  • Reimbursement Landscape

Chapter 4: Market Dynamics

  • Market Drivers
    • Government and NGO Initiatives in Creating Awareness
    • Growing Geriatric Population with Neurological Disorders
    • Increasing Global Incidence of Neurological Disorders
    • Research Initiatives in Neurology
    • Accelerated Approvals for Drugs Used in Rare Diseases
  • Market Restraints
    • Patent Expirations of Branded Drugs and Emergence of Generics
    • Adverse Side Effects
    • High Cost of Drug Development

Chapter 5: Global Market for Neurology

  • Global Market for Neurology, by Disease Indication

Chapter 6: Global Market for Parkinson Disease

  • Anti-Parkinson's Drugs: Market Overview
  • Anti-Parkinson's Drugs Market, by Drug Class
  • Dopaminergic
    • Market Size and Forecast
    • Market Analysis
  • Dopamine Agonists
    • Market Size and Forecast
    • Market Analysis
  • Enzyme Inhibitors Market
    • Market Size and Forecast
    • Market Analysis
  • Other Anti-Parkinson's Drugs
    • Market Size and Forecast
    • Market Analysis
  • Anti-Parkinson's Drugs Market, by Region
  • North America
    • Market Size and Forecast
    • Market Analysis
  • Europe
    • Market Size and Forecast
    • Market Analysis
  • Asia-Pacific
    • Market Size and Forecast
    • Market Analysis
  • South America
    • Market Size and Forecast
    • Market Analysis
  • Middle East and Africa
    • Market Size and Forecast
    • Market Analysis
  • Global Company Share Analysis

Chapter 7: Global Market for Alzheimer Disease

  • Market Overview
  • Global Alzheimer Drugs Market, by Mechanism of Action
  • AChEIs
    • Market Size and Forecast
    • Market Analysis
  • NMDA Drugs
    • Market Size and Forecast
    • Market Analysis
  • Global Alzheimer Drugs Market, by Region
  • North America
    • Market Size and Forecast
    • Market Analysis
  • Europe
    • Market Size and Forecast
    • Market Analysis
  • Rest of the World
    • Market Size and Forecast
    • Market Analysis
  • Industry Structure
    • Impact of Generic AD Therapeutics

Chapter 8: Global Market for Psychotic Disorders

  • Market Overview
  • Global Antipsychotic Drugs Market, by Drug Class
  • D2 Antagonists
    • Market Size and Forecast
    • Market Analysis
  • D2/5HT2A Antagonists
    • Market Size and Forecast
    • Market Analysis
  • D2 Partial Agonists
    • Market Size and Forecast
    • Market Analysis
  • Global Antipsychotic Drugs Market, by Region
  • North America
    • Market Size and Forecast
    • Market Analysis
  • Europe
    • Market Size and Forecast
    • Market Analysis
  • Asia-Pacific
    • Market Size and Forecast
    • Market Analysis
  • South America
    • Market Size and Forecast
    • Market Analysis
  • Middle East and Africa
    • Market Size and Forecast
    • Market Analysis
  • Global Company Share Analysis
  • Impact of Generic Antipsychotic Drugs on the Market

Chapter 9: Global Market for Epileptic Disorders

  • Market Overview
    • Market Trends
  • Global Anti-Epileptic Drugs Market, by Drug Class
  • First Generation Anti-Epileptic Drugs
    • Market Size and Forecast
    • Market Analysis
  • Second Generation Anti-Epileptic Drugs
    • Market Size and Forecast
    • Market Analysis
  • Third Generation Anti-Epileptic Drugs
    • Market Size and Forecast
    • Market Analysis
  • Global Anti-Epileptic Drugs Market, by Region
  • North America
    • Market Size and Forecast
    • Market Analysis
  • Europe
    • Market Size and Forecast
    • Market Analysis
  • Asia-Pacific
    • Market Size and Forecast
    • Market Analysis
  • South America
    • Market Size and Forecast
    • Market Analysis
  • Middle East and Africa
    • Market Size and Forecast
    • Market Analysis
  • Anti-Epileptic Drugs Market Competitive Landscape

Chapter 10: Global Market for Autism Spectrum Disorders

  • Market Overview
    • Antipsychotics
    • Antidepressants
    • Stimulants
    • Anticonvulsants
  • Global ASD Therapeutics Market, by Label Information
  • Labeled ASD Pharmaceuticals
    • Market Size and Forecast
    • Market Analysis
  • Off-label Pharmaceuticals
    • Market Size and Forecast
    • Market Analysis
  • Global ASD Therapeutics Market, by Region
  • North America
    • Market Size and Forecast
    • Market Analysis
  • Europe
    • Market Size and Forecast
    • Market Analysis
  • Rest of the World
    • Market Size and Forecast
    • Market Analysis
  • Global ASD Therapeutics Market Industry Structure

Chapter 11: Global Market for Brain Tumor Therapeutics

  • Market Overview
  • Brain Tumor Therapeutics Market, by Therapy Type
  • Chemotherapy
    • Market Size and Forecast
    • Market Analysis
  • Targeted Therapy
    • Market Size and Forecast
    • Market Analysis
  • Immunotherapy
    • Immunotherapeutic Agents
    • New Developments
  • Brain Tumor Therapeutics Market, by Region
  • North America
    • Market Size and Forecast
    • Market Analysis
  • Europe
    • Market Size and Forecast
    • Market Analysis
  • Asia-Pacific
    • Market Size and Forecast
    • Market Analysis
  • Rest of the World
    • Market Size and Forecast
    • Market Analysis
  • Company Share Analysis

Chapter 12: Pipeline Analysis

  • Overview of the Drug Development Process

Chapter 13: Competitive Landscape

  • Key Strategies Adopted by Market Players
  • Mergers and Acquisitions
  • Agreements and New Product Launches

Chapter 14: Company Profiles

  • ABBVIE
  • ACADIA PHARMACEUTICALS, INC.
  • ALEMBIC PHARMACEUTICALS LTD.
  • ALEXZA PHARMACEUTICALS
  • ALKERMES PLC
  • ALLERGAN PLC
  • APOTEX, INC.
  • ASTRAZENECA PLC
  • AUROBINDO PHARMA
  • AUTISM THERAPEUTICS
  • AVANIR PHARMACEUTICALS INC.
  • BOEHRINGER INGELHEIM
  • BRISTOL-MYERS SQUIBB CO.
  • BIOGEN
  • DAIICHI SANKYO CO., LTD.
  • DR. REDDY'S LABORATORIES LTD.
  • ELI LILLY AND CO.
  • EISAI CO. LTD.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • GEDEON RICHTER PLC
  • IMMUNOCELLULAR THERAPEUTICS, LTD.
  • JOHNSON & JOHNSON
  • LANNETT CO., INC.
  • H. LUNDBECK A/S
  • LUPIN LTD.
  • MALLINCKRODT
  • MERCK & CO
  • MYLAN NV
  • NEXTSOURCE BIOTECHNOLOGY LLC
  • NOVARTIS AG
  • OTSUKA HOLDINGS CO., LTD.
  • PFIZER INC.
  • SANOFI
  • SUMITOMO DAINIPPON PHARMA CO., LTD.
  • SUN PHARMACEUTICAL INDUSTRIES LTD. (SUN PHARMA)
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • TORRENT PHARMACEUTICALS LTD.
  • UNITED THERAPEUTICS CORP.
  • UCB SA

Chapter 15: Appendix: Acronyms

Chapter 16: References

List of Tables

  • Summary Table: Global Market for Neurology, by Disease Indication, Through 2024
    • Table 1: Current Orphan Drugs Designations for Brain Tumors
    • Table 2: Global Market for Neurology, by Disease Indication, Through 2024
    • Table 3: Global Neurology Market for Anti-Parkinson's Drugs, by Drug Class, Through 2024
    • Table 4: Global Neurology Market for Anti-Parkinson's Drugs, by Region, Through 2024
    • Table 5: Global Neurology Market for Alzheimer Drugs, by Mechanism of Action, Through 2024
    • Table 6: Global Neurology Market for Alzheimer Drugs, by Region, Through 2024
    • Table 7: Global Ranking of Leading Players in Alzheimer's Disease Drugs, by Company
    • Table 8: Global Neurology Market for Antipsychotic Drugs, by Mechanism of Action, Through 2024
    • Table 9: D2 Antagonist Drugs: Market Presence
    • Table 10: Adverse Effects Profile of D2 Antagonist/Typical Antipsychotic Drugs
    • Table 11: Global Neurology Market for Antipsychotic Drugs, by Region, Through 2024
    • Table 12: Prevalence of Serious Mental Illness Among Adults in the U.S., by State, 2017
    • Table 13: Prevalence of Mental Illness in U.S., by Disease Indication, 2017
    • Table 14: Global Neurology Market for Anti-Epileptic Drugs, by Segment, Through 2024
    • Table 15: Global Neurology Market for Anti-Epileptic Drugs, by Region, Through 2024
    • Table 16: Global Neurology Market for ASD Therapeutics, by Label Information, Through 2024
    • Table 17: Selected Late-Stage Autism Treatments
    • Table 18: Global Neurology Market for ASD Therapeutics, by Region, Through 2024
    • Table 19: Global Market Ranking of Leading Players in ASD Drugs, by Company
    • Table 20: Global Neurology Market for Brain Tumor Therapeutics, by Therapy Type, Through 2024
    • Table 21: FDA-Approved Drugs Used in Brain Tumor Chemotherapy
    • Table 22: Dosage and Administration of Temozolomide for Brain Tumors
    • Table 23: Current Brain Tumor Clinical Trials: Temozolomide
    • Table 24: Current Brain Tumor Clinical Trials Involving Lomustine
    • Table 25: Current Brain Tumor Clinical Trials involving Carmustine
    • Table 26: PCV Regimen: Brain Tumor Chemotherapy
    • Table 27: FDA Approved Targeted Therapeutic Agents for Brain Tumors
    • Table 28: Monoclonal Antibodies
    • Table 29: Small Molecule Monoclonal Antibodies
    • Table 30: Current Brain Tumor Clinical Trials Involving Bevacizumab
    • Table 31: Current Brain Tumor Clinical Trials Involving Everolimus
    • Table 32: Current Brain Tumor Clinical Trials: Immunotherapy
    • Table 33: Global Neurology Market for Brain Tumor Therapeutics, by Region, Through 2024
    • Table 34: Promising Forthcoming Neuroscience Therapies in Late Stage
    • Table 35: Agents Currently in Phase III of Alzheimer's Disease Drug Development, 2018
    • Table 36: Ongoing Clinical Trials and Product Pipeline Involving Major Players in Brain Tumor Therapeutics
    • Table 37: Acronyms Used in This Report

List of Figures

  • Summary Figure: Global Market Share for Neurology, by Disease Indication, 2018
    • Figure 1: Pharmaceutical Regulatory Pathways in the U.S and Europe
    • Figure 2: Global Market for Neurology, by Disease Indication, 2018-2024
    • Figure 3: Global Neurology Market Share for Anti-Parkinson's Drugs, by Drug Class, 2018
    • Figure 4: Global Neurology Market for Dopaminergic Drugs, 2018-2024
    • Figure 5: Global Neurology Market for Dopamine Agonist Drugs, 2018-2024
    • Figure 6: Global Neurology Market for Enzyme Inhibitors Drugs, 2018-2024
    • Figure 7: Global Neurology Market for Other Anti-Parkinson's Drugs, 2018-2024
    • Figure 8: Global Neurology Market Share for Anti-Parkinson's Drugs, by Region, 2018
    • Figure 9: North American Neurology Market for Anti-Parkinson's Drugs, 2018-2024
    • Figure 10: European Neurology Market for Anti-Parkinson's Drugs, 2018-2024
    • Figure 11: Asia-Pacific Neurology Market for Anti-Parkinson's Drugs, 2018-2024
    • Figure 12: South American Neurology Market for Anti-Parkinson's Drugs, 2018-2024
    • Figure 13: Middle Eastern and African Neurology Market for Anti-Parkinson's Drugs, 2018-2024
    • Figure 14: Global Market Share for Key Competitors of Anti-Parkinson's Drugs, 2018
    • Figure 15: Global Neurology Market for Alzheimer AChEIs Drugs, 2018-2024
    • Figure 16: Global Neurology Market for Alzheimer NMDA Drugs, 2018-2024
    • Figure 17: Global Neurology Market Share for Alzheimer Drugs, by Region, 2018
    • Figure 18: North American Neurology Market for Alzheimer Drugs, 2018-2024
    • Figure 19: European Neurology Market for Alzheimer Drugs, 2018-2024
    • Figure 20: Rest of the World Neurology Market for Alzheimer Drugs, 2018-2024
    • Figure 21: Global Neurology Market Share for Antipsychotic Drugs, by Mechanism of Action, 2018
    • Figure 22: Global Neurology Market for Antipsychotic Drugs in D2 Antagonist, 2018-2024
    • Figure 23: Global Neurology Market for Antipsychotic Drugs in D2/5HT2A Antagonist, 2018-2024
    • Figure 24: Global Neurology Market for Antipsychotic Drugs in D2 Partial Agonist, 2018-2024
    • Figure 25: Global Neurology Market Share for Antipsychotic Drugs, by Region, 2018
    • Figure 26: North American Neurology Market for Antipsychotic Drugs, 2018-2024
    • Figure 27: European Neurology Market for Antipsychotic Drugs, 2018-2024
    • Figure 28: Asia-Pacific Neurology Market for Antipsychotic Drugs, 2018-2024
    • Figure 29: South American Neurology Market for Antipsychotic Drugs, 2018-2024
    • Figure 30: Middle Eastern and African Neurology Market for Antipsychotic Drugs, 2018-2024
    • Figure 31: Global Neurology Market Share for Antipsychotic Drugs, by Manufacturer, 2018
    • Figure 32: Global Neurology Market Share for Anti-Epileptic Drugs, by Segment, 2018
    • Figure 33: Global Neurology Market for First Generation Anti-Epileptic Drugs, 2018-2024
    • Figure 34: Global Neurology Market for Second Generation Anti-Epileptic Drugs, 2018-2024
    • Figure 35: Global Neurology Market for Third Generation Anti-Epileptic Drugs, 2018-2024
    • Figure 36: Global Neurology Market Share for Anti-Epileptic Drugs, by Region, 2018
    • Figure 37: North American Neurology Market for Anti-Epileptic Drugs, 2018-2024
    • Figure 38: European Neurology Market for Anti-Epileptic Drugs, 2018-2024
    • Figure 39: Asia-Pacific Neurology Market for Anti-Epileptic Drugs, 2018-2024
    • Figure 40: South American Neurology Market for Anti-Epileptic Drugs, 2018-2024
    • Figure 41: Middle Eastern and African Neurology Market for Anti-Epileptic Drugs, 2018-2024
    • Figure 42: Global Neurology Market Share for Anti-Epileptic Drugs, by Manufacturer, 2018
    • Figure 43: Global Neurology Market Share for ASD Therapeutics, by Label Information, 2018
    • Figure 44: Global Neurology Market for Labeled ASD Drugs, 2018-2024
    • Figure 45: Global Neurology Market for Off-label Pharmaceuticals ASD, 2018-2024
    • Figure 46: Global Neurology Market Share for ASD Therapeutics, by Region, 2018
    • Figure 47: North American Neurology Market for ASD Therapeutics, 2018-2024
    • Figure 48: European Neurology Market for ASD Therapeutics, 2018-2024
    • Figure 49: Rest of the World Neurology Market for ASD Therapeutics, 2018-2024
    • Figure 50: Global Neurology Market Share for Brain Tumor Therapeutics, by Therapy Type, 2018
    • Figure 51: Global Neurology Market for Brain Tumor Chemotherapy, 2018-2024
    • Figure 52: Global Neurology Market for Brain Tumor Targeted Therapy, 2018-2024
    • Figure 53: Targeted Therapy Types
    • Figure 54: Global Neurology Market Share for Brain Tumor Therapeutics, by Region, 2018
    • Figure 55: North American Neurology Market for Brain Tumor Therapeutics, 2018-2024
    • Figure 56: North American Incidence of Brain Tumors, 2018-2040
    • Figure 57: European Neurology Market for Brain Tumor Therapeutics, 2018-2024
    • Figure 58: European Incidence of Brain Tumors, 2018-2040
    • Figure 59: Asia-Pacific Neurology Market for Brain Tumor Therapeutics, 2018-2024
    • Figure 60: Asia-Pacific Incidence of Brain Tumors, 2018-2040
    • Figure 61: ROW Neurology Market for Brain Tumor Therapeutics, 2018-2024
    • Figure 62: Shares of Major Players in Brain Tumor Therapeutics Market, 2018
Back to Top